Özçakir et al., 2004 - Google Patents
Premature luteinization defined as progesterone estradiol ratio> 1 on hCG administration day seems to adversely affect clinical outcome in long gonadotropin …Özçakir et al., 2004
- Document ID
- 11698393493023184294
- Author
- Özçakir H
- Levi R
- Tavmergen E
- Göker E
- Publication year
- Publication venue
- Journal of Obstetrics and Gynaecology Research
External Links
Snippet
Aim: To examine the effect of premature luteinization on the outcomes in long gonadotropin‐ releasing hormone agonist cycles. Methods: Two‐hundred and forty‐eight patients who had undergone assisted reproductive technology for infertility treatment between 2001 and 2002 …
- 230000002028 premature 0 title abstract description 46
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Özçakir et al. | Premature luteinization defined as progesterone estradiol ratio> 1 on hCG administration day seems to adversely affect clinical outcome in long gonadotropin‐releasing hormone agonist cycles | |
| Elnashar | Progesterone rise on the day of HCG administration (premature luteinization) in IVF: an overdue update | |
| Broer et al. | The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome | |
| Sekhon et al. | The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response | |
| Lahoud et al. | Elevated progesterone in GnRH agonist down regulated in vitro fertilisation (IVFICSI) cycles reduces live birth rates but not embryo quality | |
| Lainas et al. | Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study | |
| Sismanoglu et al. | Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial | |
| Thomsen et al. | Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin | |
| McAvey et al. | How many eggs are needed to produce an assisted reproductive technology baby: is more always better? | |
| Xi et al. | Comparison between PPOS and GnRHa-long protocol in clinical outcome with the first IVF/ICSI cycle: a randomized clinical trial | |
| Lawrenz et al. | Individualized luteal phase support | |
| Haemmerli Keller et al. | Treatment‐related psychological stress in different in vitro fertilization therapies with and without gonadotropin stimulation | |
| Palep-Singh et al. | South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts | |
| Tozer et al. | Does laparoscopic ovarian diathermy affect the outcome of IVF–embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study | |
| Tazegül et al. | Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial | |
| Lass et al. | Monitoring of in vitro fertilization–embryo transfer cycles by ultrasound versus by ultrasound and hormonal levels: a prospective, multicenter, randomized study | |
| Li et al. | Comparison of stimulated cycles with low dose r-FSH versus hormone replacement cycles for endometrial preparation prior to frozen-thawed embryo transfer in young women with polycystic ovarian syndrome: a single-center retrospective cohort study from China | |
| Inal et al. | Are there any differences between antagonist administration on days< 6 and≥ 6 of Controlled Ovarian Hyperstimulation on assisted reproductive technique outcomes? | |
| Singh et al. | Do increased levels of progesterone and progesterone/estradiol ratio on the day of human chorionic gonadotropin affects pregnancy outcome in long agonist protocol in fresh in vitro fertilization/intracytoplasmic sperm injection cycles? | |
| Berker et al. | Human menopausal gonadotropin commenced on early follicular period increases live birth rates in POSEIDON group 3 and 4 poor responders | |
| Duan et al. | No impact of treated hyperprolactinemia on cumulative live birth rate and perinatal outcomes in in vitro fertilization‐embryo transfer | |
| Ferraretti et al. | Female poor responders | |
| Atkinson et al. | GnRH agonist triggers and their use in assisted reproductive technology: the past, the present and the future | |
| Turan et al. | Outcomes of random-start letrozole protocol with PGT-A in women with breast cancer undergoing fertility preservation | |
| Schmitz et al. | Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age? |